Neogenomics Q3 2026 Results: Net Loss of $7.55M, Loss Narrows
NeoGenomics reported a net revenue increase to $209.3 million for the third quarter of 2026, up from $187.8 million in the prior year. The company significantly reduced its quarterly net loss to $7.5 million compared to $27.1 million in 2025, driven by improved gross margins and lower general and administrative expenses.
- Key figure
- Net loss $7.55M